Mon, Dec 15, 2025
[Archive]
Volume 17, Issue 3 (September-2025 2025)
Iranian Journal of Blood and Cancer 2025, 17(3): 73-78 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ibrahim Rakha N M, Elaffifi A, Abbas R, Mged G, Salah S, Sayed H. Assessment of Lysosome-Associated Membrane Protein (LAMP5) in Newly Diagnosed Multiple Myeloma Patients and Correlation to Clinical Outcome. Iranian Journal of Blood and Cancer 2025; 17 (3) :73-78
URL: http://ijbc.ir/article-1-1729-en.html
URL: http://ijbc.ir/article-1-1729-en.html
Nahed Moawad Ibrahim Rakha *1 
, Amal Elaffifi2 , Rana Abbas2 , Ghada Mged3 , Shrouk Salah2 , Haydi Sayed2
, Amal Elaffifi2 , Rana Abbas2 , Ghada Mged3 , Shrouk Salah2 , Haydi Sayed2
1- Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. , nahedrakha@med.asu.edu.eg
2- Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
3- Department of clinical pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
2- Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
3- Department of clinical pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract: (421 Views)
Introduction: Lysosome-associated membrane protein 5(LAMP5) is one of the glycosylated proteins which are implicated in several different features of cell biology and can impact cellular processes for instance phagocytosis, autophagy, lipid transference, and aging. Interestingly, it has a significant role in cancer progression, metastatic spread and aggressiveness. It has been reported to be significantly expressed in many hematopoietic malignancies as leukemias and Multiple Myeloma (MM).
Objectives: This study used enzyme-linked immunosorbent assay (ELISA) to measure the level of LAMP5 in newly diagnosed MM patients, and the level was correlated to the clinical outcome of the patient.
Methods: A prospective study was done on 64 people, including 32 newly diagnosed MM patients and 32 age- and gender-matched healthy controls. ELISA was used to assess the levels of LAMP5 in serum samples. Clinical data and LAMP5 expression correlations were assessed.
Results: MM patients’ LAMP5 levels were found to be statistically significantly higher than those of healthy controls (P<0.0001), However, LAMP5 does not correlate with clinical outcomes, laboratory results, or patient clinical data.
Conclusion: This report emphasizes that LAMP5 expression in newly diagnosed multiple myeloma patients was highly significant by ELISA and its influence on patient’s prognosis still unclear as there was no significant correlation with other clinical data, which indicates more research on large scale of patients to determine its significance of its expression on prognosis.
Objectives: This study used enzyme-linked immunosorbent assay (ELISA) to measure the level of LAMP5 in newly diagnosed MM patients, and the level was correlated to the clinical outcome of the patient.
Methods: A prospective study was done on 64 people, including 32 newly diagnosed MM patients and 32 age- and gender-matched healthy controls. ELISA was used to assess the levels of LAMP5 in serum samples. Clinical data and LAMP5 expression correlations were assessed.
Results: MM patients’ LAMP5 levels were found to be statistically significantly higher than those of healthy controls (P<0.0001), However, LAMP5 does not correlate with clinical outcomes, laboratory results, or patient clinical data.
Conclusion: This report emphasizes that LAMP5 expression in newly diagnosed multiple myeloma patients was highly significant by ELISA and its influence on patient’s prognosis still unclear as there was no significant correlation with other clinical data, which indicates more research on large scale of patients to determine its significance of its expression on prognosis.
: Original Article |
Subject:
Adults Hematology & Oncology
Received: 2025/08/11 | Accepted: 2025/09/25 | Published: 2025/09/30
Received: 2025/08/11 | Accepted: 2025/09/25 | Published: 2025/09/30
References
1. Ledergor, G., Weiner, A., Zada, M. et al. (2018). Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med 24, 1867-1876. [DOI:10.1038/s41591-018-0269-2]
2. Gracia-Maldonado G, Clark J, Burwinkel M, et al ., (2022). LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. Haematologica.; 107(4):803-815. [DOI:10.3324/haematol.2020.257451]
3. Gracia-Maldonado, G., Clark, J., Pierre, P., et al ., (2018). The Role of LAMP5 in Innate Immune Signaling Is Critical for the Survival of MLL Leukemias. Blood, 132, 3900. [DOI:10.1182/blood-2018-99-120190]
4. Rajkumar, S., Dimopoulos, M., Palumbo, A. (2014). International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15(12), e538-548. [DOI:10.1016/S1470-2045(14)70442-5]
5. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, et al., (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 10;33(26):2863-9. [DOI:10.1200/JCO.2015.61.2267]
6. Martin W. Schoen, Suhong Luo, Brian Gage, Kenneth Robert Carson, Kristen Marie Sanfilippo, (2018). Journal of Clinical Oncology, 36:15_suppl, 8051-8051. [DOI:10.1200/JCO.2018.36.15_suppl.8051]
7. Harousseau, J. L., Attal, M., & Avet-Loiseau, H.et al ., (2009). The role of complete response in multiple myeloma. Blood, The Journal of the American Society of Hematology, 114(15), 3139-3146 [DOI:10.1182/blood-2009-03-201053]
8. de Larrea C. F., Tovar N., Rozman M et al ., (2011). Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression. Biology of blood transplantation, 17(7), 1084-1087. [DOI:10.1016/j.bbmt.2010.12.707]
9. Harousseau, J. L., Attal, M., & Avet-Loiseau, H.et al ., (2009). The role of complete response in multiple myeloma. Blood, The Journal of the American Society of Hematology, 114(15), 3139-3146. [DOI:10.1182/blood-2009-03-201053]
10. Umeda S, Kanda M, Shimizu D, et al., (2022). Lysosomal associated Membrane Protein Family Member 5 Promotes the Metastatic Potential of Gastric Cancer Cells. Gastric Cancer; 25(3):558-72. [DOI:10.1007/s10120-022-01284-y]
11. Chen, Y., & Ma, T. (2023). LAMP5 may promote MM progression by activating p38. Pathology and Oncology Research, 29, 1611083. [DOI:10.3389/pore.2023.1611083]
12. Wang, H., Rueda, L. Y. M., Dang, M., Lee, et al ., (2023). Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM). Blood, 142, 873. [DOI:10.1182/blood-2023-189286]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
